914612-23-0Relevant articles and documents
Design of A Metabolically Stable Tritium-Tracer of the PI3Kδ-Inhibitor CDZ173 (Leniolisib) as a Tool to Study Liver Metabolites
Bauer, Carsten,Luu, Tong,Eggimann, Fabian,Bross, Patrick,Gertsch, Werner,Hu, Cheng,Ramstein, Philippe,Bourgailh, Julien,Gl?nzel, Albrecht,Dix, Ina,Guenat, Christian,Soldermann, Nicolas,Litherland, Karine,Desrayaud, Sandrine,Hengy, Jean-Claude,Pearson, David,Blanz, Joachim,Burkhart, Christoph
, (2018/06/21)
In this disclosure, we summarize the preliminary metabolic profiling of the PI3Kδ inhibitor CDZ173 (leniolisib, 1a) obtained from incubations of the unlabeled compound and the synthesis of its metabolically stable tritium isotopologue 1b used for metaboli
TASK CHANNEL ANTAGONISTS
-
Page/Page column 40, (2011/09/21)
This invention relates to TASK-1 and/or TASK-3 antagonists and/or their pharmaceutically acceptable salts, compositions and methods for treating and preventing disorders which are caused by activation or by an activated TASK-1 and/or TASK-3, and disorders
2-Cyanophenyl fused heterocyclic compounds, and compositions and uses thereof
-
Page/Page column 23, (2008/12/08)
Fused heterocyclic compounds are provided according to formula 1: where R1, R2, R3, and m are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others.